Brief: Peptidream Announces Pre-Clinical Results Of Oral Il-17A And Il-17F Inhibitor
17/12/2025 13:21
Dec 17 (Reuters) - PeptiDream Inc 4587.T: PEPTIDREAM ANNOUNCES PROMISING PRE-CLINICAL RESULTS OF PROPRIETARY ORAL IL-17A AND IL-17F DUAL INHIBITOR WITH BIOLOGIC-LIKE EFFICACY FOR THE TREATMENT OF PSORIASIS Source text: ID:nBw7xVVGja Further company coverage: 4587.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner